Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma
Open accessThe DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Nivolumab plus ipilimumab produced objective responses in patients with advanced renal-cell carcinoma in a pilot study. This phase 3 trial compared nivolumab plus ipilimumab with sunitinib for previously untreated clear-cell advanced renal-cell carcinoma. METHODS: We randomly assigned adults in a 1:1 ratio to receive either nivolumab (3 mg per kilogram of body weight) plus ipilimumab (1 mg per kilogram) intravenously every 3 weeks for four doses, followed by nivolumab (3 mg per kilogram) every 2 weeks, or sunitinib (50 mg) orally once daily for 4 weeks (6-week cycle). The coprimary end points were overall survival (alpha level, 0.04), objective response rate (alpha level, 0.001), and progression-free survival (alpha level, 0.009) among patients with intermediate or poor prognostic risk. RESULTS: A total of 1096 patients were assigned to receive nivolumab plus ipilimumab (550 patients) or sunitinib (546 patients); 425 and 422, respectively, had intermediate or poor risk. At a median follow-up of 25.2 months in intermediate- and poor-risk patients, the 18-month overall survival rate was 75% (95% confidence interval [CI], 70 to 78) with nivolumab plus ipilimumab and 60% (95% CI, 55 to 65) with sunitinib; the median overall survival was not reached with nivolumab plus ipilimumab versus 26.0 months with sunitinib (hazard ratio for death, 0.63; P<0.001). The objective response rate was 42% versus 27% (P<0.001), and the complete response rate was 9% versus 1%. The median progression-free survival was 11.6 months and 8.4 months, respectively (hazard ratio for disease progression or death, 0.82; P=0.03, not significant per the prespecified 0.009 threshold). Treatment-related adverse events occurred in 509 of 547 patients (93%) in the nivolumab-plus-ipilimumab group and 521 of 535 patients (97%) in the sunitinib group; grade 3 or 4 events occurred in 250 patients (46%) and 335 patients (63%), respectively. Treatment-related adverse events leading to discontinuation occurred in 22% and 12% of the patients in the respective groups. CONCLUSIONS: Overall survival and objective response rates were significantly higher with nivolumab plus ipilimumab than with sunitinib among intermediate- and poor-risk patients with previously untreated advanced renal-cell carcinoma. (Funded by Bristol-Myers Squibb and Ono Pharmaceutical; CheckMate 214 ClinicalTrials.gov number, NCT02231749 .).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Third, many of these studies utilized ICIs as monotherapy in a heavily pretreated population whereas current standard first-line therapy often includes a combination of ICIs or ICI with chemotherapy for multiple tumor types (35–40).”
From A Uniform Computational Approach Improved on Existing Pipelines to Reveal Microbiome Biomarkers of Nonresponse to Immune Checkpoint Inhibitors (2021) · cites this paper as [40]
Experimental — accuracy not yet measuredIn the citing paper
“In that study, patients were randomized either to that regimen or to sunitinib (a VEGF inhibitor); significant prolongation of PFS and overall survival was observed, with 42% of patients achieving a response (many of these durable)11,12.”
From Nivolumab plus ipilimumab with or without live bacterial supplementation in metastatic renal cell carcinoma: a randomized phase 1 trial (2022) · cites this paper as [11]
In the citing paper
“Anti-PD-1/PD-L1 agents pared with chemotherapy have also improved response rates and survival in many diseases including lung cancer, triple negative breast cancer, head and neck squamous cell carcinoma, and others.12–14”
From Endocrine toxicities of immune checkpoint inhibitors (2021) · cites this paper as [14]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay-Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,256
Safety, activity, and immune correlates of anti–PD-1 antibody in cancer
Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D., Carvajal, R. D., Sosman, J. A., Atkins, M. B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200690 · Cited by 12,628
Self-citationCombined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
Larkin, J., Chiarion-Sileni, V., Gonzalez, R., Grob, J. J., Cowey, C. L., Lao, C. D., Schadendorf, D., Dummer, R., Smylie, M., Rutkowski, P., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504030 · Cited by 8,157
Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma
Motzer, R. J., Escudier, B., McDermott, D. F., George, S., Hammers, H. J., Srinivas, S., Tykodi, S. S., Sosman, J. A., Procopio, G., Plimack, E. R., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1510665 · Cited by 5,807 · cited 1×
“Bone§ 95 (22) 97 (23) 112 (20) 119 (22)”
Self-citationSunitinib versus Interferon Alfa in Metastatic Renal-Cell Carcinoma
Motzer, R. J., Hutson, T. E., Tomczak, P., Michaelson, M. D., Bukowski, R. M., Rixe, O., Oudard, S., Negrier, S., Szczylik, C., Kim, S. T., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa065044 · Cited by 5,775 · cited 1×
“Diarrhea 145 (27) 21 (4) 278 (52) 28 (5)”
Self-citationNivolumab in Previously Untreated Melanoma without BRAF Mutation
Robert, C., Long, G. V., Brady, B., Dutriaux, C., Maio, M., Mortier, L., Hassel, J. C., Rutkowski, P., McNeil, C., Kalinka-Warzocha, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1412082 · Cited by 5,519 · cited 4×
“Female 111 (26) 121 (29) 137 (25) 151 (28)”
InfluentialTHE USE OF CONFIDENCE OR FIDUCIAL LIMITS ILLUSTRATED IN THE CASE OF THE BINOMIAL
CLOPPER, C. J., & PEARSON, E. S. (1934) · Biometrika · doi:10.1093/biomet/26.4.404 · Cited by 5,003 · cited 1×
“Bone§ 95 (22) 97 (23) 112 (20) 119 (22)”
Nivolumab plus Ipilimumab in Advanced Melanoma
Wolchok, J. D., Kluger, H., Callahan, M. K., Postow, M. A., Rizvi, N. A., Lesokhin, A. M., Segal, N. H., Ariyan, C. E., Gordon, R.-A., Reed, K., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1302369 · Cited by 4,230 · cited 1×
“Decreased appetite 75 (14) 7 (1) 133 (25) 5 (<1)”
Cited by
Items 301–400 of 1,016
Zhang, B., Wu, Q., Zhou, Y. L., Guo, X., Ge, J., & Fu, J. (2018) · International Immunopharmacology · doi:10.1016/j.intimp.2018.08.014 · Cited by 103
New emerging targets in cancer immunotherapy: the role of TIM3
Friedlaender, A., Addeo, A., & Banna, G. (2019) · ESMO Open · doi:10.1136/esmoopen-2019-000497 · Cited by 102
McKay, R. R., McGregor, B. A., Xie, W., Braun, D. A., Wei, X. X., Kyriakopoulos, C. E., Zakharia, Y., Maughan, B. L., Rose, T. L., Stadler, W. M., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.20.02295 · Cited by 103
“4246 © 2020 by American Society of Clinical Oncology Volume 38, Issue 36 With regard to toxicity, rates of grade 3-4 TRAEs and treatment discontinuation for toxicity in our study were within the rates observed with nivolumab from CheckMate0251 and nivolumab and ipilimumab from CheckMate214.”
BackgroundResultSelf-citationImmunotherapy in endometrial cancer: rationale, practice and perspectives
Cao, W., Ma, X., Fischer, J. V., Sun, C., Kong, B., & Zhang, Q. H. (2021) · Biomarker Research · doi:10.1186/s40364-021-00301-z · Cited by 112
Cytoreductive Nephrectomy — Patient Selection Is Key
Motzer, R. J., & Russo, P. (2018) · New England Journal of Medicine · doi:10.1056/nejme1806331 · Cited by 103
Self-citationTowards Immunotherapy for Pediatric Brain Tumors
Wang, S. S., Bandopadhayay, P., & Jenkins, M. R. (2019) · Trends in Immunology · doi:10.1016/j.it.2019.05.009 · Cited by 106
Sha, C. M., Lehrer, E. J., Hwang, C., Trifiletti, D. M., Mackley, H. B., Drabick, J. J., & Zaorsky, N. G. (2020) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2020.07.035 · Cited by 110
“There were 35 studies with ICI alone arms totaling 13,956 patients (Supplemental Table 3).(36-71) Disease sites include cancers of head and neck, 42 stomach, 68 melanoma, 47, 50, 51, 56, 58, 59, 61, 62, 67, 70, 71 lung, 43-45, 55, 57, 60, 63, 64, 69 kidney, 53, 54, 65 prostate,(36) and urothelial origin.”
Gutierrez, M. E., Moreno, V., Heinhuis, K. M., Olszanski, A. J., Spreafico, A., Ong, M., Chu, Q. S.-C., Carvajal, R. D., Trigo, J. M., Ochoa-de-Olza, M., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-1830 · Cited by 106
Kim, H., Shim, B. Y., Lee, S., Lee, J. Y., Lee, H. J., & Kim, I.-H. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22189795 · Cited by 117
Melero, I., Yau, T., Kang, Y.-K., Kim, T.-Y., Santoro, A., Sangro, B., Kudo, M., Hou, M.-M., Matilla, A., Tovoli, F., et al. (2024) · Annals of Oncology · doi:10.1016/j.annonc.2024.03.005 · Cited by 101
Allaf, M. E., Kim, S.-E., Master, V. A., McDermott, D. F., Harshman, L. C., Cole, S., Drake, C. G., Signoretti, S., Akgül, M., Baniak, N., et al. (2024) · The Lancet Oncology · doi:10.1016/s1470-2045(24)00211-0 · Cited by 119
Self-citationEffect of Antibiotic Use on Outcomes with Systemic Therapies in Metastatic Renal Cell Carcinoma
Lalani, A.-K. A., Xie, W., Braun, D. A., Kaymakcalan, M., Bossé, D., Steinharter, J. A., Martini, D. J., Simantov, R., Lin, X., Wei, X. X., et al. (2020) · European Urology Oncology · doi:10.1016/j.euo.2019.09.001 · Cited by 100
“Given the shift in standard of care to include combination treatment for the majority of mRCC patients [2,13], our data may better reflect the contemporary incorporation of ICIs in the evolving treatment landscape.”
BackgroundSelf-citationOrnstein, M. C., Pal, S. K., Wood, L. S., Tomer, J. M., Hobbs, B. P., Jia, X. S., Allman, K. D., Martin, A. M., Olencki, T. E., Davis, N. B., et al. (2019) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30513-3 · Cited by 100
Self-citationThe impact of hypoxia on immune state in cancer
Mortezaee, K., & Majidpoor, J. (2021) · Life Sciences · doi:10.1016/j.lfs.2021.120057 · Cited by 106
Pseudoprogression and Hyperprogression as New Forms of Response to Immunotherapy
Frélaut, M., du Rusquec, P., Moura, A. D., Tourneau, C. L., & Borcoman, É. (2020) · BioDrugs · doi:10.1007/s40259-020-00425-y · Cited by 110
“in combination with other immunotherapies [10, 11], or with chemotherapy [12–14].”
BackgroundGul, A., Stewart, T. F., Mantia, C. M., Shah, N. J., Gatof, E. S., Long, Y., Allman, K. D., Ornstein, M. C., Hammers, H. J., McDermott, D. F., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.19.03315 · Cited by 98
“More recently, the combination of nivolumab and ipilimumab, an anti–CTLA-4 antibody, was approved in the first-line setting for patients with International Metastatic Database Consortium (IMDC) intermediate- and poor-risk disease on the basis of objective response rate (ORR) and overall survival advantages compared wi…”
BackgroundSelf-citationFrom Tissue-Agnostic to N-of-One Therapies: (R)Evolution of the Precision Paradigm
Adashek, J. J., Subbiah, V., & Kurzrock, R. (2020) · Trends in cancer · doi:10.1016/j.trecan.2020.08.009 · Cited by 103
Cortiula, F., Reymen, B. J. T., Peters, S., Mol, P. V., Wauters, E., Vansteenkiste, J., Ruysscher, D. D., & Hendriks, L. E. L. (2022) · Annals of Oncology · doi:10.1016/j.annonc.2022.06.013 · Cited by 105
Imaging of T-cells and their responses during anti-cancer immunotherapy
Krekorian, M., Fruhwirth, G. O., Srinivas, M., Figdor, C. G., Heskamp, S., Witney, T. H., & Aarntzen, E. H. J. G. (2019) · Theranostics · doi:10.7150/thno.37924 · Cited by 106
“melanoma [1-3], non-small cell lung cancer [4, 5] and renal cell carcinoma [6].”
BackgroundPark, H. J., Kim, K. W., Won, S. E., Yoon, S., Chae, Y. K., Tirumani, S. H., & Ramaiya, N. H. (2021) · JAMA Network Open · doi:10.1001/jamanetworkopen.2021.1136 · Cited by 107
Bosma, N. A., Warkentin, M. T., Gan, C. L., Karim, S., Heng, D. Y. C., Brenner, D. R., & Lee‐Ying, R. M. (2022) · European Urology Open Science · doi:10.1016/j.euros.2021.12.007 · Cited by 107
“tion and not risk groups, with the exception of CheckMate 214, which investigated OS, PFS, and ORR as primary endpoints with the IO-IO agents NIVO-IPI in the intermediate/ poor risk group [14].”
BackgroundMethodInfluentialCognitive adverse effects of chemotherapy and immunotherapy: are interventions within reach?
Schagen, S. B., Tsvetkov, A. S., Compter, A., & Wefel, J. S. (2022) · Nature Reviews Neurology · doi:10.1038/s41582-021-00617-2 · Cited by 110
Tumour-wide RNA splicing aberrations generate actionable public neoantigens
Kwok, D. W., Stevers, N. O., Etxeberría, I., Nejo, T., Cove, M. C., Chen, L. H., Jung, J., Okada, K., Lakshmanachetty, S., Gallus, M., et al. (2025) · Nature · doi:10.1038/s41586-024-08552-0 · Cited by 116
CD28 costimulation drives tumor-infiltrating T cell glycolysis to promote inflammation
Beckermann, K. E., Hongo, R. A., Ye, X., Young, K. L., Carbonell, K., Contreras, D. C., Siska, P. J., Barone, S. M., Roe, C. E., Smith, C. C., et al. (2020) · JCI Insight · doi:10.1172/jci.insight.138729 · Cited by 105
“Specifically, CD8 + T cells in tumor as compared with adjacent kidney tissue or matched peripheral blood had subsets with high expression of HLA-DR and PD-1, in agreement with previous publications (30).”
InfluentialWu, Z., Chen, Q., Qu, L., Li, M., Wang, L., Mir, M. C., Carbonara, U., Pandolfo, S. D., Black, P. C., Paul, A. K. R., et al. (2022) · European Urology · doi:10.1016/j.eururo.2022.01.028 · Cited by 103
The efficacy and safety of combination of PD-1 and CTLA-4 inhibitors: a meta-analysis
Wu, K., Yi, M., Qin, S., Chu, Q., Zheng, X., & Wu, K. (2019) · Experimental Hematology & Oncology · doi:10.1186/s40164-019-0150-0 · Cited by 96
Zhang, Y., Schoenhals, J. E., Christie, A. L., Mohamad, O., Wang, C., Bowman, I. A., Singla, N., Hammers, H. J., Courtney, K. D., Bagrodia, A., et al. (2019) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2019.07.023 · Cited by 96
Self-citationThe evolving role of PD-L1 testing in patients with metastatic urothelial carcinoma
Powles, T. B., Walker, J., Williams, J. A., & Joaquim Bellmunt, B. (2019) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2019.101925 · Cited by 97
Self-citationImmunomodulatory Roles of VEGF Pathway Inhibitors in Renal Cell Carcinoma
Hirsch, L., Flippot, R., Escudier, B. J., & Albiges, L. K. (2020) · Drugs · doi:10.1007/s40265-020-01327-7 · Cited by 102
“The restoration of anti-tumor T-cell functions by ICI has led to durable objective tumor responses and improved OS in patients with mRCC [12, 13].”
BackgroundSelf-citationLabriola, M., Zhu, J., Gupta, R. T., McCall, S. J., Jackson, J., Kong, E., White, J. R., Cerqueira, G. C., Gerding, K., Simmons, J. K., et al. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2019-000319 · Cited by 103
Yeo, E. C. F., Brown, M. P., Gargett, T., & Ebert, L. M. (2021) · Cells · doi:10.3390/cells10030607 · Cited by 106
“ICI therapy has revolutionised anti-cancer therapy for many patients with solid cancers such as melanoma and kidney cancer [10,11].”
BackgroundClear Cell Renal Cell Carcinoma: From Biology to Treatment
Kase, A. M., George, D. J., & Ramalingam, S. (2023) · Cancers · doi:10.3390/cancers15030665 · Cited by 109
“Nivolumab (Opdivo®, Bristol Myers Squibb), a PD-1 inhibitor, became the first immune checkpoint inhibitor approved for the management of advanced RCC in 2015.”
BackgroundInfluentialLi, Q. K., Pavlovich, C. P., Zhang, H., Kinsinger, C. R., & Chan, D. W. (2018) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2018.06.004 · Cited by 108
Mutational and Antigenic Landscape in Tumor Progression and Cancer Immunotherapy
Vitale, I., Sistigu, A., Manic, G., Rudqvist, N.-P., Trajanoski, Z., & Galluzzi, L. (2019) · Trends in Cell Biology · doi:10.1016/j.tcb.2019.01.003 · Cited by 94
Gu, L., Khadaroo, P. A., Su, H., Kong, L., Chen, L., Wang, X., Li, X., Zhu, H., Zhong, X., Pan, J., et al. (2019) · BMC Cancer · doi:10.1186/s12885-019-5785-z · Cited by 102
Soldi, R., Ghosh, T., Weston, A., Thode, T. G., Drenner, K., Lewis, R., Kaadige, M. R., Srivastava, S., Ampanattu, S. D., del Villar, R. R., et al. (2020) · PLoS ONE · doi:10.1371/journal.pone.0235705 · Cited by 98
“In renal cell carcinoma, patients carrying mutations in bromodomain-containing 92 genes (PBRM1 and BRD8) showed exceptional response to the anti-CTLA-4 antibody Ipilimumab 93 (38).”
Clinical Pharmacology and Interplay of Immune Checkpoint Agents: A Yin-Yang Balance
Geraud, A., Gougis, P., Vozy, A., Anquetil, C., Allenbach, Y., Romano, E., Funck-Brentano, E., Moslehi, J. J., Johnson, D. B., & Salem, J.-E. (2021) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-022820-093805 · Cited by 96
SLAMF7 Signaling Reprograms T Cells toward Exhaustion in the Tumor Microenvironment
O’Connell, P., Hyslop, S., Blake, M. K., Godbehere, S., Amalfitano, A., & Aldhamen, Y. A. (2020) · The Journal of Immunology · doi:10.4049/jimmunol.2000300 · Cited by 102
Missiaen, R., Mazzone, M., & Bergers, G. (2018) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2018.06.002 · Cited by 94
“…was not associated with progression-free survival (PFS), angiogenesis, T-effector/IFN-γ response, and myeloid inflammatory gene expression signatures were strongly and differentially associated with PFS within and across the treatments suggestive of using those as potential biomarkers [143] [144].”
Flynn, M. J., Sayed, A. A., Sharma, R., Siddique, A., & Pinato, D. J. (2018) · Hepatology · doi:10.1002/hep.30337 · Cited by 98
The adjuvant treatment of kidney cancer: a multidisciplinary outlook
Porta, C., Cosmai, L., Leibovich, B. C., Powles, T. B., Gallieni, M. A., & Bex, A. (2019) · Nature Reviews Nephrology · doi:10.1038/s41581-019-0131-x · Cited by 102
Self-citationLiu, J., Kong, X., Huang, T., Wang, R., Li, W., & Chen, Q. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.02048 · Cited by 103
Johannet, P. M., Sawyers, A., Qian, Y., Kozloff, S., Gulati, N., Donnelly, D. M., Zhong, J., & Osman, I. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-001674 · Cited by 102
Cancer-Associated Angiogenesis: The Endothelial Cell as a Checkpoint for Immunological Patrolling
Solimando, A. G., Summa, S. D., Vacca, A., & Ribatti, D. (2020) · Cancers · doi:10.3390/cancers12113380 · Cited by 98
“Nonetheless, the toxicity profile is higher [49,52].”
Atkins, M. B., Jegede, O. A., Haas, N. B., McDermott, D. F., Bilen, M. A., Stein, M., Sosman, J. A., Alter, R., Plimack, E. R., Ornstein, M. C., et al. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.21.02938 · Cited by 105
“12 months before treatment initiation and/or before an intervening treatment, (3) looking at end points such as median PFS or OS that may be poor measures of immunotherapy efficacy rather than ORR and landmark survival, (4) using mixed combination regimens that do not isolate the impact of the anti–PD-(L)1 component (…”
ResultSelf-citationBoilève, A., Carlo, M. I., Barthélémy, P., Oudard, S. M., Borchiellini, D., Voss, M. H., George, S., Chevreau, C., Landman‐Parker, J., Tabone, M.-D., et al. (2018) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-018-0482-z · Cited by 97
“Conversely, the combination of ipilimumab and nivolumab is the standard of care for intermediate and poor risk disease [7].”
BackgroundSelf-citationOnuma, A. E., Zhang, H., Huang, H., Williams, T. M., Noonan, A. M., & Tsung, A. (2020) · Gene Expression · doi:10.3727/105221620x15880179864121 · Cited by 99
Elkrief, A., Pidgeon, R., Vareki, S. M., Messaoudene, M., Castagner, B., & Routy, B. (2025) · Nature Reviews Drug Discovery · doi:10.1038/s41573-025-01211-7 · Cited by 109
Rizzo, A., Mollica, V., Santoni, M., Ricci, A. D., Rosellini, M., Marchetti, A., Montironi, R., Ardizzoni, A., & Massari, F. (2022) · European Urology Focus · doi:10.1016/j.euf.2021.03.001 · Cited by 91
Ishihara, H., Takagi, T., Kondo, T., Homma, C., Tachibana, H., Fukuda, H., Yoshida, K., Iizuka, J., Kobayashi, H., Okumi, M., et al. (2019) · Urologic Oncology: Seminars and Original Investigations · doi:10.1016/j.urolonc.2019.03.003 · Cited by 92
Chahoud, J., Msaouel, P., Campbell, M. T., Bathala, T. K., Xiao, L., Gao, J., Zurita, A. J., Shah, A. Y., Jonasch, E. W., Sharma, P., et al. (2019) · The Oncologist · doi:10.1634/theoncologist.2019-0372 · Cited by 91
“The observed best ORR with nivolumab in patients with metastatic nccRCC is consistent with the reported activity in ccRCC [11, 12].”
ResultSelf-citationPD-1/PD-L1 Based Combinational Cancer Therapy: Icing on the Cake
Zhang, J., Yan, Y., Li, J., Adhikari, R., & Fu, L. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.00722 · Cited by 101
“Further study showed that treatment-related adverse events, grade 3 or 4 events, and treatment-related adverse events leading to discontinuation were lower in the nivolumab-plus-ipilimumab group than in the sunitinib group (Motzer et al., 2018).”
BackgroundYan, X. Q., Ye, M., Zou, Q., Chen, P., He, Z. S., Wu, B., He, D., He, C. H., Xue, X., Ji, Z., et al. (2023) · Annals of Oncology · doi:10.1016/j.annonc.2023.09.3108 · Cited by 105
Heinhuis, K. M., Carlino, M. S., Joerger, M., Nicola, M. D., Meniawy, T. M., Rottey, S., Moreno, V., Gazzah, A., Delord, J., Paz-Ares, L. G., et al. (2019) · JAMA Oncology · doi:10.1001/jamaoncol.2019.3848 · Cited by 92
Capturing Hyperprogressive Disease with Immune-Checkpoint Inhibitors Using RECIST 1.1 Criteria
Matos, I. G., Martín-Liberal, J., García-Ruiz, A., Hierro, C., de Olza, M. O., Viaplana, C., Azaro, A., Vieito, M., Braña, I., Mur, G., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-2226 · Cited by 98
“Most of these approvals have been based on phase III clinical trials that compared ICIs with chemotherapy or targeted therapies as standard treatments in a wide range of malignancies such as melanoma(1-3), non-smallcell lung cancer (NSCLC)(4-8), head and neck squamous-cell carcinoma (HNSCC)(9, 10), urothelial carcinom…”
MethodSystematic Review of PD-1/PD-L1 Inhibitors in Oncology: From Personalized Medicine to Public Health
Chang, E., Pelosof, L. C., Lemery, S. J., Gong, Y. U. T., Goldberg, K. B., Farrell, A. T., Keegan, P., Veeraraghavan, J., Wei, G., Blumenthal, G. M., et al. (2021) · The Oncologist · doi:10.1002/onco.13887 · Cited by 99
Triple negative breast cancer: Immunogenicity, tumor microenvironment, and immunotherapy
Loizides, S., & Constantinidou, A. (2023) · Frontiers in Genetics · doi:10.3389/fgene.2022.1095839 · Cited by 103
“Immunotherapy, the most rapidly evolving field in oncology, has revolutionized the treatment of multiple cancers, including melanoma non-small cell lung cancer and renal cell carcinoma (Brahmer et al., 2017; Hodi et al., 2018; Motzer et al., 2018; Mok et al., 2019).”
BackgroundLipid-based nanosystems: the next generation of cancer immune therapy
Cheng, Z., Fobian, S., Gurrieri, E., Amin, M., D’Agostino, V., Falahati, M., Zalba, S., Debets, R., Garrido, M. J., Saeed, M., et al. (2024) · Journal of Hematology & Oncology · doi:10.1186/s13045-024-01574-1 · Cited by 106
Dudani, S., Graham, J., Wells, J. C., Bakouny, Z., Pal, S. K., Dizman, N., Donskov, F. N., Porta, C., de Velasco, G., Hansen, A. R., et al. (2019) · European Urology · doi:10.1016/j.eururo.2019.07.048 · Cited by 90
Self-citationSex and Gender Differences in Kidney Cancer: Clinical and Experimental Evidence
Peired, A. J., Campi, R., Angelotti, M. L., Antonelli, G., Conte, C., Lazzeri, E., Becherucci, F., Calistri, L., Serni, S., & Romagnani, P. (2021) · Cancers · doi:10.3390/cancers13184588 · Cited by 107
Kluger, H. M., Barrett, J. C., Gainor, J. F., Hamid, O., Hurwitz, M. E., LaVallee, T. M., Moss, R. A., Zappasodi, R., Sullivan, R. J., Tawbi, H. A., et al. (2023) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-005921 · Cited by 101
Combination regimens with PD-1/PD-L1 immune checkpoint inhibitors for gastrointestinal malignancies
Wang, D., Lin, J., Yang, X., Long, J., Bai, Y., Yang, X., Mao, Y., Sang, X., Seery, S., & Zhao, H. (2019) · Journal of Hematology & Oncology · doi:10.1186/s13045-019-0730-9 · Cited by 90
Mutations in renal cell carcinoma
D’Avella, C. A., Abbosh, P. H., Pal, S. K., & Geynisman, D. M. (2018) · Urologic Oncology Seminars and Original Investigations · doi:10.1016/j.urolonc.2018.10.027 · Cited by 99
Kim, J., Kim, B., Kang, S. Y., Heo, Y. J., Park, S. H., Kim, S. T., Kang, W. K., Lee, J., & Kim, K. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.00314 · Cited by 98
Gleeson, J. P., Nikolovski, I., DiNatale, R. G., Zucker, M. R., Knežević, A., Patil, S., Ged, Y. M. A., Kotecha, R. R., Shapnik, N., Murray, S. J., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-4367 · Cited by 92
Self-citationRuste, V., Goldschmidt, V., Laparra, A., Messayke, S., Danlos, F., Romano‐Martin, P., Champiat, S., Voisin, A.-L., Baldini, C., Massard, C., et al. (2021) · European Journal of Cancer · doi:10.1016/j.ejca.2021.08.048 · Cited by 94
CHI3L1 regulates PD-L1 and anti–CHI3L1–PD-1 antibody elicits synergistic antitumor responses
Ma, B., Akosman, B., Kamle, S., Lee, C.-M., He, C. H., Koo, J. S., Lee, C. G., & Elias, J. A. (2021) · Journal of Clinical Investigation · doi:10.1172/jci137750 · Cited by 95
Exhausted intratumoral Vδ2− γδ T cells in human kidney cancer retain effector function
Rancan, C., Arias-Badia, M., Dogra, P., Chen, B., Aran, D., Yang, H., Luong, D., Ilano, A., Li, J., Chang, H., et al. (2023) · Nature Immunology · doi:10.1038/s41590-023-01448-7 · Cited by 98
The Immunobiology of Kidney Cancer
Drake, C. G., & Stein, M. N. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2018.79.2648 · Cited by 104
Juloori, A., Katipally, R. R., Lemons, J. M., Singh, A. K., Iyer, R. V., Robbins, J. R., George, B., Hall, W. A., Pitroda, S. P., Arif, F., et al. (2022) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2022.09.052 · Cited by 96
Targeting the PD-1/PD-L1 Pathway in Renal Cell Carcinoma
Kammerer‐Jacquet, S., Deleuze, A., Saout, J., Mathiéu, R., Laguerre, B., Verhoest, G., Dugay, F., Belaud‐Rotureau, M., Bensalah, K., & Rioux-Leclercq, N. C. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20071692 · Cited by 92
“confirmed the benefit of the nivolumab and ipilimumab association versus sunitinib in first line metastatic RCC [39].”
BackgroundComplete response of renal cell carcinoma vena cava tumor thrombus to neoadjuvant immunotherapy
Labbate, C. V., Hatogai, K., Werntz, R. P., Stadler, W. M., Steinberg, G. D., Eggener, S. E., & Sweis, R. F. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0546-8 · Cited by 90
Hahn, A. W., Klaassen, Z. W. A., Agarwal, N., Haaland, B. A., Esther, J., Ye, X. Y., Wang, X., Pal, S. K., & Wallis, C. J. D. (2019) · European Urology Oncology · doi:10.1016/j.euo.2019.09.002 · Cited by 93
Alaiwi, S. A., Xie, W., Nassar, A. H., Dudani, S., Martini, D. J., Bakouny, Z., Steinharter, J. A., Nuzzo, P. V., Flippot, R., Chanzá, N. M., et al. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2019-000144 · Cited by 96
Self-citationPender, A., Titmuss, E., Pleasance, E., Fan, K. Y., Pearson, H., Brown, S. D., Grisdale, C. J., Topham, J. T., Shen, Y., Bonakdar, M., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-1163 · Cited by 96
“Clin Cancer Res; 27(1) January 1, 2021 CLINICAL CANCER RESEARCH 204”
BackgroundInfluentialImmunotherapy in renal cell carcinoma: latest evidence and clinical implications
Santoni, M., Massari, F., Nunno, V. D., Conti, A., Cimadamore, A., Scarpelli, M., Montironi, R., Liang Cheng, C., Battelli, N., & Antonio Lopez-beltran, B. (2018) · Drugs in Context · doi:10.7573/dic.212528 · Cited by 86
“Looking to CheckMate 214 results, it is probable that this positive effect could be restricted in patients with specific clinical features such as intermediate/poor-risk disease; whereas, patients with a favourable profile could benefit more from a standard treatment [14].”
BackgroundFiglin, R. A., Tannir, N. M., Uzzo, R. G., Tykodi, S. S., Chen, D. Y. T., Master, V. A., Kapoor, A., Vaena, D. A., Lowrance, W. T., Bratslavsky, G., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-2427 · Cited by 91
“Moreover, the treatment options for patients with previously untreated advanced RCC is continually evolving with promising results from trials employing combination of pembrolizumab plus axitinib (26) or nivolumab plus ipilimumab (8) in the first-line setting.”
BackgroundSelf-citationHeme oxygenase-1 orchestrates the immunosuppressive program of tumor-associated macrophages
Alaluf, E., Vokaer, B., Detavernier, A., Azouz, A., Splittgerber, M., Carrette, A., Boon, L., Libert, F., Soares, M. P., Moine, A. L., et al. (2020) · JCI Insight · doi:10.1172/jci.insight.133929 · Cited by 113
Regev, A., Avigan, M. I., Kiazand, A., Vierling, J. M., Lewis, J. H., Omokaro, S. O., Di Bisceglie, A. M., Fontana, R. J., Bonkovsky, H. L., Freston, J. W., et al. (2020) · Journal of Autoimmunity · doi:10.1016/j.jaut.2020.102514 · Cited by 83
Is There a Role for Immunotherapy in Prostate Cancer?
Rizzo, A., Mollica, V., Cimadamore, A., Santoni, M., Scarpelli, M., Giunchi, F., Cheng, L., López-Beltrán, A., Fiorentino, M., Montironi, R., et al. (2020) · Cells · doi:10.3390/cells9092051 · Cited by 92
“Two meaningful examples are the impressive complete response rate of 10% achieved with nivolumab plus ipilimumab combination in metastatic renal cell carcinoma in Checkmate 214 trial and the survival benefits provided by immune checkpoint monoclonal antibodies in metastatic malignant melanoma where—until the approval…”
BackgroundSystematic review of combinations of targeted or immunotherapy in advanced solid tumors
Tan, A. C., Bagley, S. J., Wen, P. Y., Lim, M. K., Platten, M., Colman, H., Ashley, D. M., Wick, W., Chang, S. M., Galanis, E., et al. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-002459 · Cited by 95
The oligometastatic spectrum in the era of improved detection and modern systemic therapy
Katipally, R. R., Pitroda, S. P., Juloori, A., Chmura, S. J., & Weichselbaum, R. R. (2022) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-022-00655-9 · Cited by 94
Treatment strategies for clear cell renal cell carcinoma: Past, present and future
Yang, J., Wang, K., & Yang, Z. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1133832 · Cited by 107
“4 months, respectively, in the sunitinib-treated group (74).”
First and Second-line Treatments in Metastatic Renal Cell Carcinoma
Barragán-Carrillo, R., Saad, E., Saliby, R. M., Sun, M., Albiges, L. K., Bex, A., Heng, D. Y. C., Méjean, A., Motzer, R. J., Plimack, E. R., et al. (2024) · European Urology · doi:10.1016/j.eururo.2024.10.019 · Cited by 101
Self-citationGeorge, S., Rini, B. I., & Hammers, H. J. (2019) · JAMA Oncology · doi:10.1001/jamaoncol.2018.4604 · Cited by 84
Self-citationIncorvaia, L., Fanale, D., Badalamenti, G., Porta, C., Olive, D., Luca, I. D., Brando, C., Rizzo, M., Messina, C. G. M., Rediti, M., et al. (2020) · OncoImmunology · doi:10.1080/2162402x.2020.1832348 · Cited by 93
“However, although a clinically relevant median response duration is reported, not all patients equally benefit from the currently available IO treatment, and the patient response rate is overall low.(17) Biological factors specific for certain individuals have a clear effect on this variation in response.”
BackgroundSelf-citationThe Tumor Microenvironment Factors That Promote Resistance to Immune Checkpoint Blockade Therapy
Russell, B. L., Sooklal, S. A., Malindisa, S. T., Daka, L. J., & Ntwasa, M. M. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.641428 · Cited by 86
“Its approval was subsequently expanded for the treatment of various cancers including cervical cancer (59), gastric cancer (60), urothelial cancer (8), Hodgkin’s lymphoma (6), hepatocellular carcinoma (9), squamous cell carcinoma (13, 61), colorectal cancer (3), non-small cell lung cancer (10), diffuse large B-cell ly…”
BackgroundPalmer, A. C., Izar, B., Hwangbo, H., & Sorger, P. K. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-2275 · Cited by 79
Ni, J., Zhang, Z., Ge, M.-J., Chen, J., & Zhuo, W. (2022) · Acta Pharmacologica Sinica · doi:10.1038/s41401-022-00953-z · Cited by 89
Immune Checkpoint Inhibitors for the Treatment of Central Nervous System (CNS) Metastatic Disease
Kamath, S. D., & Kumthekar, P. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00414 · Cited by 84
“As a result, the 10 mg/kg dose is uncommon in more recent clinical trials, especially when dual immunotherapy is used, where the 1–3 mg/kg doses are often used (18, 19).”
BackgroundFicial, M., Jegede, O. A., Sant’Angelo, M., Hou, Y., Flaifel, A., Pignon, J., Braun, D. A., Wind‐Rotolo, M., Sticco-Ivins, M. A., Catalano, P. J., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-3084 · Cited by 89
“Nivolumab (nivo; an anti–PD-1 ICI) attained FDA approval as a second-line therapy in advanced ccRCC (1), whereas the combination of nivo and ipilimumab (an anti–CTLA-4 ICI) was FDA-approved as a first-line therapy in patients with advanced ccRCC based on the results of the CheckMate-214 trial (2).”
BackgroundSelf-citationWang, B., Yin, H., Zhang, Y., Zhao, Q., Wang, H., Wei, J., Meng, L., Xin, Y., & Jiang, X. M. (2023) · Cell & Bioscience · doi:10.1186/s13578-023-01073-9 · Cited by 92
Validity of data extraction in evidence synthesis practice of adverse events: reproducibility study
Xu, C., Yu, T., Furuya-Kanamori, L., Lin, L., Zorzela, L., Zhou, X., Dai, H., Loke, Y., & Vohra, S. (2022) · BMJ · doi:10.1136/bmj-2021-069155 · Cited by 82
Inflammatory and Infectious Syndromes Associated With Cancer Immunotherapies
Fishman, J. A., Hogan, J. I., & Maus, M. V. (2018) · Clinical Infectious Diseases · doi:10.1093/cid/ciy1025 · Cited by 86
Adjuvant therapy in renal cell carcinoma
Gul, A., & Rini, B. I. (2019) · Cancer · doi:10.1002/cncr.32144 · Cited by 82
“ICIs targeting the PD-1/PD-L1 and CTLA-4 pathways demonstrated significant antitumor activity in patients with mRCC.(42) The ability of ICIs to maintain antitumor efficacy even after their discontinuation generated interest in evaluating ICIs in the adjuvant setting.”
BackgroundSelf-citationRecent Advances and Challenges in the Treatment of Rhabdomyosarcoma
Miwa, S., Yamamoto, N., Hayashi, K., Takeuchi, A., Igarashi, K., & Tsuchiya, H. (2020) · Cancers · doi:10.3390/cancers12071758 · Cited by 101
Carretero-González, A., Lora, D., Martín-Sobrino, I., Sanz, I. S., Bourlon, M. T., Herranz, U. A., Chanzá, N. M., Castellano, D., & de Velasco, G. (2020) · Cancers · doi:10.3390/cancers12071945 · Cited by 92
“Currently, the IMDC score remains as the only useful strategy for treatment selection (restricting the use of the nivolumab plus ipilimumab combination for the intermediate risk- and poor risk-patients) [4].”
BackgroundMethodSelf-citationTerry, S., Dalban, C., Rioux-Leclercq, N. C., Adam, J., Meylan, M., Buart, S., Bougoüin, A., Lespagnol, A., Dugay, F., Moreno, I. C., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-0972 · Cited by 100
“It will be important to explore the connections between AXL, microenvironment components, and therapeutic outcomes in the context of other treatment regimens, namely the anti–PD-1/antiCTLA4 combination emerging as a standard-of-care first-line therapy option (10, 30), anti–PDL1–based combinations used to treat patient…”
BackgroundSelf-citationSantoni, M., Buti, S., Myint, Z. W., Maruzzo, M., Iacovelli, R., Pichler, M., Kopecký, J., Kucharz, J., Rizzo, M., Galli, L., et al. (2023) · European Urology Oncology · doi:10.1016/j.euo.2023.07.003 · Cited by 94
Self-citationLiu, X., Guo, C., Tou, F., Wen, X., Kuang, Y., Zhu, Q., & Hu, H. (2019) · International Journal of Cancer · doi:10.1002/ijc.32744 · Cited by 87
Metadata
- Authors
- Motzer, R. J., Tannir, N. M., McDermott, D. F., Arén Frontera, O., Melichar, B., Choueiri, T. K., Plimack, E. R., Barthélémy, P., Porta, C., George, S., Powles, T., Donskov, F., Neiman, V., Kollmannsberger, C. K., Salman, P., Gurney, H., Hawkins, R., Ravaud, A., Grimm, M.-O., Bracarda, S., Barrios, C. H., Tomita, Y., Castellano, D., Rini, B. I., Chen, A. C., Mekan, S., McHenry, M. B., Wind-Rotolo, M., Doan, J., Sharma, P., Hammers, H. J., & Escudier, B.
- Affiliations
- Brigham and Women's Hospital (US)
- From Memorial Sloan Kettering Cancer Center, New York (R.J.M.), and Roswell Park Cancer Institute, Buffalo (S.G.) — both in New York; University of Texas M.D. Anderson Cancer Center, Houston (N.M.T., P. Sharma); Beth Israel Deaconess Medical Center, Dana–Farber/Harvard Cancer Center (D.F.M.), and Dana–Farber Cancer Institute, Brigham and Women’s Hospital, and Harvard Medical School (T.K.C.), Boston; Centro Internacional de Estudios Clínicos (O.A.F.) and Fundación Arturo López Pérez (P. Salman),...
- ORCID
- Motzer, Robert J.
- Tannir, Nizar M.
- McDermott, David F.
- Melichar, Bohuslav
- Choueiri, Toni K.
- Plimack, Elizabeth R.
- Barthélémy, Philippe
- Porta, Camillo
- George, Saby
- Powles, Thomas
- Donskov, Frede
- Kollmannsberger, Christian K.
- Salman, Pamela
- Gurney, Howard
- Ravaud, Alain
- Grimm, Marc-Oliver
- Barrios, Carlos H.
- Tomita, Yoshihiko
- Castellano, Daniel
- Rini, Brian I.
- Mekan, Sabeen
- McHenry, M. Brent
- Sharma, Padmanee
- Hammers, Hans J.
- Escudier, Bernard
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2018-04-05
- Volume
- 378
- Issue
- 14
- Pages
- 1277-1290
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC5972549
- OpenAlex
- W2792937256
- Cited by
- 4,656
- References
- 31
- Citations by year
- 2026: 305 · 2025: 416 · 2024: 510 · 2023: 601 · 2022: 656 · 2021: 708 · 2020: 684 · 2019: 562 · 2018: 209
- FWCI
- 408.20
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Ghent University Academic Bibliography (Ghent University) (submittedVersion, other-oa)
- LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas) (submittedVersion, other-oa)
- CINECA IRIS Institutional Research Information System (University of Bari Aldo Moro) (submittedVersion, other-oa)
- Tampere University Institutional Repository (Tampere University) (submittedVersion)
- Funders
- Bristol-Myers Squibb
- Ono Pharmaceutical Company Limited
- Topics
- Health Sciences › Medicine › Oncology › Renal cell carcinoma treatment
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Ferroptosis and cancer prognosis
- Keywords
- nivolumab plus ipilimumab, sunitinib, advanced renal cell carcinoma, clear cell renal cell carcinoma, immune checkpoint inhibitors, PD-1 inhibitors, CTLA-4 inhibitors, combination immunotherapy, overall survival, objective response rate, progression-free survival, treatment-related adverse events, immune-related adverse events, first-line therapy
- MeSH terms
- Antineoplastic Agents, Immunological, Ipilimumab, Sunitinib, Nivolumab, Adult, Aged, Aged, 80 and over, Antibodies, Monoclonal, Antineoplastic Combined Chemotherapy Protocols, Carcinoma, Renal Cell, Humans, Indoles, Kidney Neoplasms, Male, Middle Aged, Pyrroles, Quality of Life, Risk, Survival Rate, Survival Analysis, Disease-Free Survival
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.